Now, the growing buzz around the use of GLP-1 medications like Ozempic to treat alcohol use disorder finally has new clinical ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

The case for GLP-1 drugs like Ozempic possibly causing blindness is building. A new paper out this week describes several ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease ...

These compounds take a different approach to weight loss than existing medications, which can cause nausea, vomiting and ...

Research links weight loss medications like Ozempic and Zepbound to certain serious eye conditions.

GLP-1 hormones interact with receptors in multiple brain regions to induce various physiological responses affecting an individual’s reward regulation. The hormone is synthesized in the nucleus ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

New research explores the wide world of the positives, and potential drawbacks, of new obesity medications. And each brings a new consideration for physicians.